CLENE INC (CLNN)
US1856342019 - Common Stock
CLENE INC
NASDAQ:CLNN (1/14/2025, 8:00:01 PM)
4.8
-0.15 (-3.03%)
Company Profile
Clene Inc. is a US-based company operating in Biotechnology industry. The company is headquartered in Salt Lake City, Utah and currently employs 82 full-time employees. The company went IPO on 2018-08-27. Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. The company specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.
Company Info
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121
P: 18016769695
CEO: Robert Etherington
Employees: 82
Website: https://clene.com/
CLNN News
2 days ago - NewMediaWireIBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALSSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
a month ago - Clene Inc.FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALSFDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform...
2 months ago - Clene Inc.Clene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsClene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval...
3 months ago - Clene Inc.Clene to Present at Upcoming October ConferencesSALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene...
4 months ago - NewMediaWireIBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private PlacementsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
4 months ago - Clene Inc.Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt FacilityInvestment led by healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s...
CLNN Twits
Here you can normally see the latest stock twits on CLNN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
